Iconovo - Asset Resilience Ratio

Latest as of June 2026: 3.83%

Iconovo (ICO) has an Asset Resilience Ratio of 3.83% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ICO net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Skr6.21 Million
≈ $668.73K USD Cash + Short-term Investments

Total Assets

Skr162.44 Million
≈ $17.48 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Iconovo's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Iconovo's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Iconovo's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read ICO total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr0.00 0%
Short-term Investments Skr6.21 Million 3.83%
Total Liquid Assets Skr6.21 Million 3.83%

Asset Resilience Insights

  • Limited Liquidity: Iconovo maintains only 3.83% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Iconovo Industry Peers by Asset Resilience Ratio

Compare Iconovo's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Cochlear Ltd
AU:COH
Medical Devices 9.76%
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
Medical Devices 0.84%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 34.37%
Stratec SE
XETRA:SBS
Medical Devices 0.29%
Shinhung
KO:004080
Medical Devices 4.17%
DRTECH Corporation
KQ:214680
Medical Devices 5.18%
Novacyt
PA:ALNOV
Medical Devices 0.02%
Diagnostic Medical Systems SA
PA:ALDMS
Medical Devices 1.48%

Annual Asset Resilience Ratio for Iconovo (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Iconovo.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 3.76% Skr4.93 Million
≈ $530.44K
Skr131.08 Million
≈ $14.11 Million
+0.28pp
2024-12-31 3.48% Skr5.07 Million
≈ $545.51K
Skr145.69 Million
≈ $15.68 Million
-14.75pp
2023-12-31 18.22% Skr23.34 Million
≈ $2.51 Million
Skr128.08 Million
≈ $13.78 Million
+7.14pp
2022-12-31 11.09% Skr13.45 Million
≈ $1.45 Million
Skr121.27 Million
≈ $13.05 Million
-52.82pp
2021-12-31 63.91% Skr94.94 Million
≈ $10.22 Million
Skr148.54 Million
≈ $15.99 Million
+2.86pp
2020-12-31 61.05% Skr61.69 Million
≈ $6.64 Million
Skr101.04 Million
≈ $10.87 Million
-17.33pp
2019-12-31 78.38% Skr89.16 Million
≈ $9.59 Million
Skr113.75 Million
≈ $12.24 Million
+5.41pp
2018-12-31 72.97% Skr53.05 Million
≈ $5.71 Million
Skr72.70 Million
≈ $7.82 Million
+19.58pp
2017-12-31 53.39% Skr22.48 Million
≈ $2.42 Million
Skr42.10 Million
≈ $4.53 Million
-3.99pp
2016-12-31 57.39% Skr11.54 Million
≈ $1.24 Million
Skr20.11 Million
≈ $2.16 Million
--
pp = percentage points

About Iconovo

ST:ICO Sweden Medical Devices
Market Cap
$12.26 Million
Skr113.96 Million SEK
Market Cap Rank
#26622 Global
#561 in Sweden
Share Price
Skr1.19
Change (1 day)
-0.42%
52-Week Range
Skr0.93 - Skr2.39
All Time High
Skr95.00
About

Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreeme… Read more